Projects
Develop Estimated Net Present Value Model for an Innovative De Novo Protein Drug Targeting Crohn’s Disease
Process Development for a De Novo Protein Targeting Interleukin 23 (IL23) Receptor
Process Development for other De Novo Proteins
Responsibilities
- Researched on process development for protein expression in E. coli with an emphasis on scaling up.
- Transformed plasmids into E. coli and tested protein expressions in various cultures medium
- Analyzed nucleic acid sequences to predict protein behaviors
- Developed standard operating procedures for expressing and purifying de novo designed proteins utilizing PEI precipitation, Ion Exchange Chromatography (IC), Immobilized metal affinity chromatography (IMAC), and Size Exclusion Chromatography (SEC)
- Built an excel net present value (NPV) model to predict the future cash flow of an interleukin-23 receptor inhibitor as potential treatment for Crohn’s Disease (CD)
